Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

41.75
+1.212.98%
Post-market: 41.750.00000.00%19:30 EDT
Volume:2.42M
Turnover:100.91M
Market Cap:7.00B
PE:107.54
High:41.96
Open:41.03
Low:40.32
Close:40.54
52wk High:55.67
52wk Low:27.00
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.95
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:3.87
PE(LYR):29.20

Loading ...

Alkermes Plc - Lumryz Safety Profile in Revitalyz Study Consistent With Known Safety Data

THOMSON REUTERS
·
May 12

Alkermes Announces Positive Topline Results From Revitalyz℠ Phase 3 Study Evaluating Lumryz® (Sodium Oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

THOMSON REUTERS
·
May 12

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Maravai Lifesciences Holdings (MRVI) and Alkermes (ALKS)

TIPRANKS
·
May 11

Analysts Offer Insights on Healthcare Companies: Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS)

TIPRANKS
·
May 11

Alkermes price target raised to $50 from $45 at Needham

TIPRANKS
·
May 07

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Benzinga Earnings
·
May 07

Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says

MT Newswires Live
·
May 07

UBS Adjusts Price Target on Alkermes Public to $48 From $42, Maintains Buy Rating

MT Newswires Live
·
May 06

Alkermes (ALKS) Receives a Buy from Wells Fargo

TIPRANKS
·
May 06

Alkermes Plc : Needham Raises Target Price to $50 From $45

THOMSON REUTERS
·
May 06

Alkermes Is Maintained at Buy by Needham

Dow Jones
·
May 06

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
May 06

Stock Track | Alkermes PLC Soars 5.03% Intraday on Strong Q1 Earnings Beat and Phase 3 Clinical Program Initiation

Stock Track
·
May 06

GUIDANCE: (ALKS) Alkermes Expects 2026 Revenue Range $1.73B - $1.84B, vs. FactSet Est of $1.80B

MT Newswires Live
·
May 05

Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss

MT Newswires Live
·
May 05

Alkermes Q1 FY26 net loss widens to $66.5 million; revenue climbs to $392.9 million

Reuters
·
May 05

Alkermes Plc Q1 Total Revenue $392.9 Mln

THOMSON REUTERS
·
May 05

Alkermes Plc Q1 Shr Loss 0.40

THOMSON REUTERS
·
May 05

Alkermes Q1 EPS $(0.40) Beats $(0.52) Estimate, Sales $392.911M Beat $359.848M Estimate

Benzinga Earnings
·
May 05

Alkermes Plc: Alixorexton Brilliance Phase 3 Narcolepsy Clinical Program Initiated in Q1 2026

THOMSON REUTERS
·
May 05